Endocrine Society's Annual Meeting to Feature Data on VIVUS' Qnexa
MOUNTAIN VIEW, Calif., June 16 /PRNewswire-FirstCall/ -- VIVUS,
Inc. (NASDAQ:VVUS) today announced that data on
Qnexa®, an investigational drug candidate, will be presented at
the Endocrine Society's 92nd Annual Meeting and Expo (ENDO) in San
Diego, California. Timothy Garvey, M.D., professor of medicine and
chair of the department of nutrition sciences at the University of
Alabama at Birmingham and a Qnexa investigator, will deliver an
oral presentation at the Clinical Trials Symposium on Saturday,
June 19, entitled: "Once-Daily, Low-Dose, Controlled-Release
Phentermine/Topiramate Demonstrates Significant Improvement in
Weight, Related Risk in Overweight/Obese Patients with
Comorbidities."
"We are pleased to have a significant presence at this year's
ENDO meeting, where Dr. Timothy Garvey will present data that
further illustrate the potential impact that Qnexa, if approved,
may have on life-threatening weight-related comorbidities,
including cholesterol, blood pressure and diabetes," stated Wesley
Day, PhD, vice president, clinical development at VIVUS. "We look
forward to sharing these important data with our colleagues in the
endocrinology community."
Following are details about the upcoming presentation: The Endocrine Society's 92nd Annual Meeting and Expo, San Diego, Calif. Date and Time: Saturday, June 19, 2010, 3:45-4 PM PDT Session: Clinical Trials Symposium Abstract: S19-5
Presentation Title: Once-Daily, Low-Dose, Controlled-Release
Phentermine/Topiramate Demonstrates Significant Improvement in
Weight, Related Risk in Overweight/Obese Patients with
Comorbidities
Location: Room 29ABC, San Diego Convention Center Presenter: W. Timothy Garvey, M.D. About VIVUS
VIVUS is a biopharmaceutical company developing innovative,
next-generation therapies to address unmet needs in obesity, sleep
apnea, diabetes and sexual health. The company's lead product in
clinical development, Qnexa®, has completed phase 3 clinical
trials for the treatment of obesity and an NDA has been filed and
accepted by the FDA, with an action date of October 28, 2010. Qnexa
is also in phase 2 clinical development for the treatment of type 2
diabetes and obstructive sleep apnea. In the area of sexual health,
VIVUS is in phase 3 development with avanafil, a potentially
best-in-class PDE5 inhibitor for the treatment of erectile
dysfunction. MUSE® (alprostadil), a first generation therapy
for the treatment of ED, is already on the market and generating
revenue for VIVUS. For more information about the company, please
visit www.vivus.com.
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as "anticipate," "believe," "forecast,"
"estimated" and "intend," among others. These forward-looking
statements are based on VIVUS' current expectations and actual
results could differ materially. There are a number of factors that
could cause actual events to differ materially from those indicated
by such forward-looking statements. These factors include, but are
not limited to, substantial competition; uncertainties of patent
protection and litigation; uncertainties of government or third
party payer reimbursement; reliance on sole source suppliers;
limited sales and marketing efforts and dependence upon third
parties; risks related to the development of innovative products;
and risks related to failure to obtain FDA clearances or approvals
and noncompliance with FDA regulations. As with any pharmaceutical
under development, there are significant risks in the development,
regulatory approval and commercialization of new products. There
are no guarantees that future clinical studies discussed in this
press release will be completed or successful or that any product
will receive regulatory approval for any indication or prove to be
commercially successful. VIVUS does not undertake an obligation to
update or revise any forward-looking statement. Investors should
read the risk factors set forth in VIVUS' Form 10-K for the year
ended December 31, 2009 and periodic reports filed with the
Securities and Exchange Commission.
CONTACT:
--------
VIVUS, Inc. Investor Relations: The Trout Group
Timothy E. Morris Brian Korb
Chief Financial Officer 646-378-2923
650-934-5200
Media Relations: Pure Communications, Inc.
Dan Budwick
973-271-6085
Source: VIVUS, Inc.
CONTACT: Timothy E. Morris, Chief Financial Officer of VIVUS,
Inc.,
+1-650-934-5200; or Investors, Brian Korb of The Trout Group,
+1-646-378-2923;
or Media, Dan Budwick of Pure Communications, Inc.,
+1-973-271-6085, both for
VIVUS, Inc.
Web Site: http://www.vivus.com/
Posted: June 2010
